Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats
Autor: | Teppei Ito, Mei Yamada, Hiromi Kimura-Suda, Yuya Kanehira, Hirotaka Wagatsuma, Tetsuo Yano, Daisuke Inoue |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Vitamin medicine.medical_specialty Combination therapy Endocrinology Diabetes and Metabolism BMD bone mineral density 030209 endocrinology & metabolism Diseases of the musculoskeletal system Article MIN minodronate Eldecalcitol Minodronate FTIR imaging 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Orthopedics and Sports Medicine ELD eldecalcitol OVX ovariectomized micro-CT micro-computed tomography ALN alendronate Bone mineral ALF alfacalcidol RIS risedronate Risedronate Alendronate Chemistry Fourth lumbar vertebra medicine.anatomical_structure Endocrinology FTIR Fourier transform infrared RC925-935 BPs bisphosphonates Ovariectomized rat Cortical bone 030101 anatomy & morphology |
Zdroj: | Bone Reports Bone Reports, Vol 14, Iss, Pp 101061-(2021) |
ISSN: | 2352-1872 |
Popis: | Combination therapy of active vitamin D3 with some bisphosphonates (BPs) has been reported to be clinically beneficial. However, combination therapy of eldecalcitol (ELD) with BP has to date not been validated as to whether it is beneficial in the clinical setting. Preclinical studies suggested that simultaneous treatment with ELD and some BPs is more effective than monotherapy. However, the relative potency of various BPs, when used in combination with ELD, is completely unknown. In this study, we examined and compared the effects of risedronate (RIS), alendronate (ALN), and minodronate (MIN) alone or in combination with ELD on bone mass, microarchitecture, strength, and material properties in ovariectomized Sprague-Dawley rats aged 13 weeks. RIS, ALN, MIN, and ELD were administered five times weekly for 16 weeks. Micro-computed tomography analysis, compression test, and Fourier transform infrared (FTIR) imaging analysis were performed 16 weeks after treatment initiation. Trabecular and cortical bone mineral density (BMD) in the fourth lumbar vertebra (L4) significantly increased in the RIS + ELD, ALN + ELD, and MIN + ELD groups compared with the vehicle group. Moreover, the bone microarchitecture of L4 in all the BP + ELD groups also significantly improved. On mechanical testing of L4, the maximum load was significantly increased in the RIS + ELD and ALN + ELD groups. FTIR analysis revealed that the mineral-to-collagen ratio of trabecular bone in L3 of all the BP + ELD groups was significantly increased compared with the vehicle group. By contrast, the carbonate-to-phosphate ratio, a parameter of mineral immaturity, was significantly decreased in the RIS + ELD and ALN + ELD groups. BP + ELD improved the BMD and structural properties of the bone to a similar extent. RIS + ELD and ALN + ELD also improved bone strength. Furthermore, treatment with BP + ELD improved the bone material. These results suggest that the combination therapy of BP and ELD is beneficial and warrants further clinical trials. Highlights • Combination of bisphosphonates and eldecalcitol was superior to either monotherapy. • Bone quality on FTIR imaging analysis correlated with bone strength. • Combined bisphosphonate and eldecalcitol may be useful in the clinical setting. |
Databáze: | OpenAIRE |
Externí odkaz: |